Please assess the completion status of the following clinical trial:

Trial Title: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men or women aged 18-60 years. Able and willing to provide informed consent.~* Presence of HIV-1 infection as documented by a licensed ELISA test kit and confirmed by Western blot or HIV RNA.~* Track A (Currently taking E/C/F/TDF or E/C/F/TAF): Taking E/C/F/TDF or E/C/F/TAF for at least 3 months prior to screening and undetectable plasma HIV-1 RNA (≤ 40 copies/mL)~* Track B (Currently not taking ART): Off ART for at least 3 months. Prior exposure to TDF and FTC will be allowed but subjects must not have primary genotypic drug resistance mutations to elvitegravir, tenofovir, or emtricitabine (see Exclusion Criteria)~* Plasma HIV-1 RNA ≥ 5,000c/mL and CD4+ T-cell count ≥200cells/mm3.~Exclusion Criteria:~* Track B: Presence of primary drug resistance mutations for EVG, tenofovir, or emtricitabine.~* Use of drugs of abuse or alcohol which would interfere with adherence or completion of this study. While on-study, subjects will be instructed not to consume alcohol for 48 hours prior to pharmacokinetic sampling days.~* Pregnancy or breast-feeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to study entry and day of entry.~* Chronic, severe, or other medical conditions that, in the opinion of the investigator, would interfere with the subjects ability to participate in the protocol.~* Use of prohibited protocol-specified drugs, prescription or over-the-counter, within 14 days prior to study entry.~* Bleeding abnormality or other contraindication to lumbar puncture.~* Moderate or severe cognitive impairment by history or based on Montreal Cognitive Assessment.~* Hepatitis B surface antigen (HBsAg) positive (Positive anti-HBs antibody and negative HBsAg results are acceptable)~* Hepatitis C antibody (HCV Ab) positive~* Laboratory parameters documented within 21 days prior to study entry that would increase the risk for adverse events:~  1. Hemoglobin \< 12.5 g/dL for men; \< 11.5 g/dL for women;~ 2. Platelet count \< 100,000 platelets/mm3;~ 3. AST (SGOT) or ALT (SGPT) \> 1.5 x the upper limit of normal (ULN);~ 4. Estimated GFR\<70 ml/min~ 5. Weight less than 50 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Stribild Arm (Type: OTHER): Stribild Arm is for participants taking Stribild at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
- Genvoya Arm (Type: OTHER): Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.
- Untreated Arm (Type: OTHER): Untreated Arm is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete